SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variant. (30th June 2022)

• Record Type: Journal Article
• Authors: Chechet, Gloria D; Kwaga, Jacob K P; Yahaya, Joseph; Noyes, Harry; MacLeod, Annette; Adamson, Walt E
• Is Part Of: International journal of epidemiology. Volume 51:Number 5(2022)
• Page Start: 1361
• Page End: 1370
• Publication Date: 2022-06-30
• Subjects: SARS-CoV-2 -- Covid-19 -- seroprevalence -- Kaduna -- Nigeria; Epidemiology -- Periodicals; 614.4
• DOI: 10.1093/ije/dyac141
• Languages: English
• ISSNs: 0300-5771

Abstract

Abstract: Background: Nigeria is Africa's most populated country. By November 2021 it had experienced three waves of SARS-CoV-2 infection. Peer-reviewed seroprevalence data assessing the proportion of the Nigerian population that have been infected were extremely limited. Methods: We conducted a serosurvey in one urban site ( n = 400) and one rural site ( n = 402) in Kaduna State, Nigeria between 11 October 2021 and 8 November 2021. Z-tests were used to compare seroprevalence across age groups, locations and sexes. T tests were used to determine whether age or household size are associated with seropositivity. Associations between seropositivity and recent history of common Covid-19 symptoms were tested using logistic regression. Results: SARS-CoV-2 antibodies were detected in 42.5% an 53.5% of participants at the urban and rural sites, respectively The overall age- and sex- stratified seroprevalence was 43.7% (42.2% for unvaccinated individuals). The data indicate an infection rate in Kaduna State ≥359-fold the rate derived from polymerase chain reaction-confirmed cases. In the urban site, seroprevalence among females and participants aged <20 was lower than other groups. Reporting loss of sense of taste and/or smell was strongly associated with seropositive status. Associations with seropositivity were also found for the reporting of dry cough, fever, headache, nausea and sore throat. Conclusions: This study provides baseline SARS-CoV-2 seroprevalence in Kaduna State, Nigeria, immediately prior to the spread of the Omicron variant. It indicates that in October/November 2021, approximately 56% of the population did not have detectable antibodies, and population subgroups with particularly low seroprevalence remain. It highlights limitations in using PCR-confirmed cases to estimate infection rates. The data will inform public health strategies in Nigeria and other sub-Saharan African countries with limited SARS-CoV-2 seroprevalence data.